相关实验视频
Updated: May 10, 2026

09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
概括
将静脉血压降低到小于130毫米升的水平,可能有利于最近患有缺口性中风的患者. 虽然这对所有中风事件都没有统计学意义,但这一目标显著降低了脑内出血率.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 临床试验 临床试验
背景情况:
- 在缺口性心脏病发作后预防复发性中风的最佳血压目标尚未确立.
- 众所周知,降低血压可以预防最初的中风,但其在二次预防lacunar中风的有效性需要进一步研究.
研究的目的:
- 研究不同缩血压目标对近期缺口性中风患者中复发性中风率的影响.
- 为了确定较低的血压目标 (<130毫米升) 是否比更高的目标 (130-149毫米升) 更有效地预防复发性中风.
主要方法:
- 一项随机的开放性试验,涉及3020名近期患有MRI定义的症状性缺口性心脏病发作的患者,遍及北美,拉丁美洲和西班牙.
- 患者被分配到130-149毫米平或130毫米平以下的缩血压目标.
- 主要终点是所有中风事件的减少,包括缺血性中风和内出血. 进行了治疗意向分析.
主要成果:
- 经过平均3.7年的随访后,较低血压的目标群体 (平均SBP 127 mm Hg) 在所有中风 (HR 0.81) 和致残/致死性中风 (HR 0.81) 中显示出非显著的减速率.
- 与较高目标组相比,较低目标组观察到脑内出血率 (HR 0.37) 的显著降低 (平均SBP 138 mm Hg).
- 心肌梗塞或血管死亡的综合结局也显示了较低目标的非显著减少 (HR 0.84). 与治疗相关的严重不良事件是罕见的.
结论:
- 虽然整体中风事件的减少没有达到统计学意义,但研究结果表明,在最近发生沟性中风的患者中,准静脉压低于130毫米的血压可能有潜在的益处.
- 脑内出血率的显著降低支持该患者群体中降低血压目标的安全性和潜在有效性.
相关概念视频
Pre-Procedural Guidelines for Assessing Blood Pressure
Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the patient.
Sites for measuring blood pressure
Blood pressure measurement is a fundamental clinical procedure, providing crucial data for assessing cardiovascular health. Among the various sites for this measurement, the brachial and popliteal arteries are predominantly utilized due to their accessibility and the reliability of their readings. This lesson delves into the anatomical significance, methodology, and considerations of measuring blood pressure at these locations.
The Brachial Artery: Primary Site for Blood Pressure Measurement
The Brachial Artery: Primary Site for Blood Pressure Measurement
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...